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Osteolytic bone disease is a common manifestation of multiple myeloma (MM) that leads
to progressive skeleton destruction and is the most severe cause of morbidity in MM
patients. It results from increased osteolytic activity and decrease osteoblastic function.
Activation of mammalian chitinases chitotriosidase (CHIT1) and YKL40 is associated with
osteoclast (OCs) differentiation and bone digestion. In the current study, we investigated
the effect of two Bortezomib’s concentration (2.5 and 5 nM) on osteoclastogenesis
by analyzing regulation of chitinase expression. OCs exposition to bortezomib (BO)
was able to inhibit the expression of different OCs markers such as RANK, CTSK,
TRAP, and MMP9. In addition BO-treatment reduced CHIT1 enzymatic activity and both
CHIT1 and YKL40 mRNA expression levels and cytoplasmatic and secreted protein.
Moreover, immunofluorescence evaluation of mature OCs showed that BO was able to
translocate YKL40 into the nucleus, while CHIT1 remained into the cytoplasm. Since
MM cell lines such as U266, SKM-M1 and MM1 showed high levels of CHIT1 activity,
we analyzed bone resorption ability of U266 using dentin disk assay resorption pits.
Silencing chitinase proteins in U266 cell line with specific small interfering RNA, resulted
in pits number reduction on dentine disks. In conclusion, we showed that BO decreases
osteoclastogenesis and reduces bone resorption in OCs and U266 cell line by modulating
the chitinases CHIT1 and YKL40. These results indicate that chitinases may be a
therapeutic target for bone disease in MM patients.
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Introduction
Multiple myeloma (MM) is a clonal B-cell malignancy characterized by accumulation of clonal
plasma cells (PCs) in the bone marrow (BM) leading to bone destruction and BM failure. Osteolytic
bone disease is a common manifestation of MM that leads to a progressive destruction of the
skeleton. This is the most severe cause of morbidity because of pathological fractures, spinal
cord compression, chronic bone pain and extreme disability (Mundy, 1998; Terpos et al., 2013).
Abbreviations: BO, bortezomib; CHIT1, chitotriosidase; DDs, dentin disks; MM, multiple myeloma; MMP9, Matrix
metallopeptidase 9; OCs, osteoclasts; siRNA, small interfering RNA; YKL40, chitinase 3-like-1.
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Pathogenetic mechanisms of MM bone destruction are closely
linked to MM PC and osteoclasts (OCs) hyperactivity coupled
with defective osteoblast (OB) function unable to counteract bone
resorption. It has been demonstrated that malignant PC alter
the cellular composition of the bone (Noll et al., 2014). MM
cells promote osteoclastogenic effect both by exerting themselves
bone destruction and through recruitment, differentiation and
activation of OC progenitors within the BM (Calvani et al.,
2005). In response to PC, tumor associated stromal cells,
that physiologically differentiate into OBs produce numerous
pro-osteoclastogenic factors increasing OC recruitment and
OC-mediated bone loss at sites proximal to the PC tumor
(Farrugia et al., 2003; Heider et al., 2005; Zannettino et al.,
2005). OCs are large multinucleated cells that arise from
precursors of the mononuclear-phagocytic lineage through
increased levels of receptor activator of nuclear factor kB
ligand (RANKL) and M-CSF, whose intracellular pathways
propagate signals that activate sequential transcription factors,
resulting in the production of major OC enzymes that drive
specific functions such as acidification and degradation of
the bone matrix (Fujikawa et al., 1996; Bahar et al., 2007;
Silvestris et al., 2009). Many studies have demonstrated an
increase of RANKL, the major osteoclast-activating factors, in
the MM BM microenvironment (Sezer et al., 2002; Heider
et al., 2003). In OCs, RANKL/RANK binding activates TRAF6
(tumor necrosis factor receptor-associated factor 6) which
activates AP-1 (activator protein-1), NF-kB (nuclear factor
kappa B), and p38 MAPK inducing the transcription of OCs
promoting genes (von Metzler et al., 2007). The regulation of the
transcriptional activity of AP-1 and NF-kB transcription factors
also occurs by the proteasome-ubiquitin system. A constitutively
increased proteasome activity has been reported in myeloma cells
(Jakob et al., 2007). Bortezomib (BO) is the first proteasome
inhibitor approved for treatment of MM patients. The drug
induces the stabilization of NF-kB antagonist I-kB and AP-1
transcription factors c-Fos and c-Jun resulting in reduction of
OCs differentiation (vonMetzler et al., 2007; Hongming and Jian,
2009).
Mammalian chitinases belong to the glycohydrolase family
18, which have evolved to hydrolyze chitin, a polymer of
N-acetylglucosamine (Herrera-Estrella and Chet, 1999).
The family of chitinases includes members both with and
without glycohydrolase enzymatic activity against chitin.
Chitotriosidase (CHIT1) and acidic mammalian chitinase
(CHIA or AMCAse) are the only two true chitinase possessing
chitinolytic (glycohydrolase) activities (Boot et al., 2001). In
contrast, chitinase-like-lectins (Chi-lectins) or chitinase-like
proteins (C/CLPs), including chitinase 3-like-1 (CHI3L1,
YKL40, HC-gp39), chitinase 3-like-2 (CHI3L2, CHIL2, YKL-39),
chitinase domain containing 1 (CHID1), show enzymatic activity
despite the retention and conservation of the substrate-binding
cleft of the chitinases (van Aalten et al., 2001). Elevated levels of
chitinases have been reported in a variety of diseases including
infections, chronic inflammation and degenerative disorders
(Malaguarnera, 2006; Di Rosa and Malaguarnera, 2012). In
particular, a recent study showed that the activation of alternative
macrophage is involved in osteolysis and suggested a correlation
between CHIT1 and osteolytic lesions (Koulouvaris et al., 2008).
Moreover, it was observed that in patients with myeloma elevated
serum concentrations of YKL40 worsened bone destruction
and were associated with an increase of bone resorption activity
hastening the progression of bone disease (Mylin et al., 2008). In
rat model of cold I/R injury, some authors demonstrated that the
upregulation of YKL-40 is a mechanisms responsible for steatotic
liver I/R injury and this can be abrogated with the administration
of BO (Tiriveedhi et al., 2014).
A recent study of our group demonstrated that CHIT1 and
YKL40 have a crucial role in osteoclastogenesis and in osteolysis
mediated by matrix metalloproteinase-9 (MMP9; Di Rosa et al.,
2014). In the current work, we investigated the effect of BO
on chitinases expression during osteoclastogenesis. In addition,
we also evaluated the expression of chitinases in MM cell lines




The U266, SKM-M1, and MM1 were obtained from American
Type Culture Collection (Manassas, VA, USA). The cell
lines were maintained in RPMI medium containing 2 mM
l-glutamine, supplemented with 10% fetal bovine serum (FBS)
and intermittently with 100 U/ml penicillin and 100 mg/ml
streptomycin at a humidified 37°C incubator providing 5%
CO2. Human monocytes were isolated, after informed consent,
from fresh buffy coat of healthy volunteers provided by the
Transfusional Centre “Garibaldi” Hospital, Catania, S. Immuno-
Haematology and Transfusional Medicine. Monocytes then were
purified from the lymphomonocytic population by positive
isolation using magnetic beads coated with goat anti-mouse
CD14+ IgG (Miltenyi Biotec GmbH, Germany). Analysis of
monocytes was performed by multicolor FACS (Cytomics FC
500, Beckman Coulter) using the following antibodies (Beckman
Coulter): anti-CD14 and anti-CD11c. Monocytes, identified as
CD14+ CD11c+ cells, showed purity greater than 90% (data not
showed).
In Vitro OCs Differentiation
Monocytes isolated from PBMCs were cultured at a density
of 5  105 cells/cm2 in 24-well culture plates in conditioned
IMDM supplemented with 10% FBS, 2 mM glutamine, and 1%
of penicillin/streptomycin (Invitrogen, Milan, Italy). In order to
obtain OCs, the conditioned medium was supplemented with
25 ng/ml soluble rhRANK ligand (PeproTech. BDA, Italy) and
20 ng/ml rhM-CSF (PeproTech. BDA, Italy), for 21 days w/o
BO (2.5 or 5 nM). The medium was replaced every 3 days and
supernatants were harvested for enzymatic assay. To confirm
that macrophages achieved OCs differentiation, suitable markers
were analyzed by real-time PCR (qRT-PCR). Finally, in order to
evaluate the ability ofMMcell lines (U266) to digest bone, dentine
disks were added to the wells before cell seeding. U266 cultured
with conditioned medium (without BO) for 24 h were used as a
control.
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Gene Expression Analysis by Real-Time PCR
After RNA extraction and reverse transcription, we evaluated
expression of the following mRNA: CHIT1 (Hs00185753_m1),
YKL40 (Hs01072228_m1), MMP9 (Hs00234579_m1), CTSK
(Hs00166156_m1), TRAP (Hs00356261_m1). Their expression
was assessed by TaqMan Gene Expression (Applied Biosystem)
and quantified using a fluorescence-based real-time detection
method by 7900HT Fast Start (Applied Biosystem). For each
sample, the relative expression level of each studied mRNA
was normalized using GAPDH (Hs02758991_g1) as invariant
controls.
Western Blot
Cells were harvested by trypsinization and total proteins were
extracted using M-PER cell lysis buffer (THERMO Scientific,
USA). The lysates were collected forWestern blot analysis. Protein
concentrations were determined according to the Bradford
method.
Protein levels were visualized by immunoblotting
with antibodies against human CHIT1 (sc-99033, Santa
Cruz Biotechnology, USA), YKL40 (sc-30465, Santa Cruz
Biotechnology, USA), MMP9 (sc-13520, Santa Cruz
Biotechnology, USA) and GAPDH (sc-365062, Santa
Cruz Biotechnology, USA). Briefly, 30 mg of lysate supernatant
was resolved by SDS/polyacrylamide gel electrophoresis on
4–20% Mini-PROTEAN® TGX™(BIO-RAD, Milan, Italy) and
transferred to a nitrocellulose membrane trans-Blot Turbo
mini nitrocellulose (BIO-RAD, Milan, Italy) using a semidry
transfer apparatus (BIO-RAD, Hercules, CA, USA). The
membranes were incubated with 5% milk in 10 mM Tris-HCl
(pH 7.4), 150 mM NaCl, 0.05% Tween 20 (TBST) buffer at
4°C overnight. After washing with TBST, the membranes
were incubated with a 1:2000 dilution of anti-CHIT1, anti-
YKL40, anti-MMP9 or anti-GAPDH antibodies for 1 h at
room temperature with constant shaking. The filters were then
washed and probed with horseradish peroxidase-conjugated
anti-rabbit IgG-HRP (Santa Cruz Biotechnology, USA) for
CHIT1, donkey anti-goat IgG-HRP (Santa Cruz Biotechnology,
USA) for YKL40 and MMP9 and goat anti-mouse IgM-HRP
(Santa Cruz Biotechnology, USA) for GAPDH at a dilution of
1:2000. Chemiluminescence detection was performed with the
Amersham ECL detection kit according to the manufacturer’s
instructions.
Determination of Supernatant Proteins
Culture supernatants (100ml) were collected and stored at 20°C,
at the indicated time points and used for protein extraction.
Briefly 900 ml of 100% isopropanol was added and centrifuged at
12,000 g for 15min. The pellet was dissolved inM-PER (100ml)
and solubilized proteins (5 ml, 20 mg) from all samples were
electrophoresed on 12% SDS/polyacrylamide gel and transferred
to nitrocellulose membrane to performWestern blot analysis.
Immunofluorescence
Cells were grown directly on coverslips before immunofluore-
scence. After washing with phosphate-buffered saline (PBS), cells
were fixed in methanol–acetone (1:1) for 10 min at  20°C
and then washed three times for 5 min in PBS. Subsequently,
coverslips were incubated with the primary antibody anti-CHIT1
(Santa Cruz Biotechnology, USA) and anti-YKL40 (Santa Cruz
Biotechnology, USA) diluted 1:400 in PBS containing 0.1% Tween
20 and 1% BSA overnight at +4°C. Cells were washed as above
before incubation with secondary antibody, Alexa Fluor 594-
conjugated Affini Pure goat-anti-rabbit IgG for CHIT1 and
Alexa Fluor 594-conjugated Affini Pure donkey-anti-goat IgG
for YKL40, diluted 1:500 in PBS and 0.1% Tween 20 and 1%
BSA, then washed once more as above. Finally, coverslips were
mounted on microscope slides with Ultracruz TM anti-fade
medium containing 40,6-diamidino-2-phenylindole (DAPI; Santa
Cruz Biotechnology). Localization of CHIT1 and YKL40was then
performed by using a confocal laser scanningmicroscopy (CLSM;
Zeiss LSM700).
Chitotriosidase Activity Assay
Chitotriosidase enzymatic activity was determined in cell-free
supernatants of the OCs at different stages of differentiation. The
activity was determined by a fluorimetric method using 22 mM
4-methylumbelliferyl b D-NNN-triacetylchitotriosidase (Sigma
Chemical Co.) in citrate–phosphate buffer, pH 5.2, as previously
described (Di Rosa et al., 2005).
Fluorescence was read at 450 nm with a Perkin Elmer LS40
fluorimeter (excitation wavelength 365 nm). As control, cell-free
supernatants ofmonocytes cultured for 24 hwere used. Enzymatic
activity was measured as nanomoles of substrate hydrolyzed per
ml per hour (nmol/ml/h).
Cell Transfection and siRNA
Multiplemyeloma cell lines (U266)were cultured in six-well plates
at a density between 2.5 and 5  105 cells/ml for 24 h. Cells
were transfected with small interfering RNA (siRNA; 20 nM)
targeting CHIT1 (Santa Cruz Biotechnology, Inc.) and YKL40
(Santa Cruz Biotechnology, Inc.) in the presence of siRNA
transfection reagent (Santa Cruz Biotechnology, Inc.), according
to the manufacturer’s instructions. Control cells were transfected
with scrambled random siRNA (Santa Cruz Biotechnology, Inc.).
The cells were incubated for 96 h before collection.
Resorption Assay
The U266 cell line and the OCs cells (5  104/cm2) were plated
onto dentine disks (Osteosite Dentine Disks, Immunodiagnostic
Systems Inc., Fountain Hills, AR, USA) in 96-well plates for
the digestion test. After 24 h, the cells were treated with
siRNA, as described above in materials and methods. After
96 h, the cells were removed with 5% sodium hypochlorite for
10 min. Disks were rinsed with water and stained with 1%
(w/v) toluidine blue in 0.5% sodium borate for 30 s and then
washed twice with water. Individual pits or multiple pit clusters
were observed and counted using a microscope at 25–100
magnification. Four microscopic field observation were used to
count the number of resorption pits. Results were expressed as
the number of resorption pits. Experiments were performed in
triplicate.
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FIGURE 1 | The figure shows a significant reduction (p<0.0001) of OCs marker in the cells treated with 2.5 and 5 nM with BO compared to the
negative control (OCs not treated) (A). Determination of resorption pits on dentin disk showed a significant reduction of bone matrix digestion (47.65%, p=0.005)
in the cells treated with BO 2.5 nM and in the cells treated with BO 5 nM (21%, p=0.005), compared to the control (OCs without BO) (B). The treatment with BO
determined a modulation of chitinases. CHIT1 mRNA expression was decreased in a dose-dependent manner in presence of BO (2.5 nM) respect to monocytes
without BO (ctrl; p<0.003) and BO 5 nM (p<0.003). BO was capable of decrease also the mRNA expression of YKL40, about onefold at BO 2.5 nM and with a




The MTT assay was performed to detect cell viability. Briefly,
cells were seeded in 96-well plates at 1  103 cells/well, and then
were treated with siRNAs as previously described. After 48 h of
siRNA treatment, 20 ml of MTT solution (5 mg/ml) was added
to each well. After 3 h of incubation, formazan crystals were
dissolved in 150 ml of 0.1 M HCl in isopropanol. Color intensity
was measured at 570 nm with ELISA plate reader (THERMO
Multiskan FC).
Statistical Analysis
Data are expressed as mean  standard error (SD). Significance
was assessed byANOVAor Student’s t test. p<0.05was considered
to be statistically significant.
Results
BO Inhibits OCs Differentiation
To detect whether BO was able to modulate the process of OC
differentiation, we treated monocytes with RANKL (25 ng/ml),
MCSF (20 ng/ml) and w/o BO for 21 days. Cell viability did not
change after BO exposure (data not shown). Expression of OCs
markers (MMP9, RANK, CTSK, and TRAP) and bone matrix
digestion were investigated after 21 days of culture. We detected a
significant reduction both of OCs markers expression (p<0.0001)
and of the ability of bone digestion in OCs after BO exposure
(Figures 1A,B).
We recently demonstrated that CHIT1 and YKL40 have a
crucial role in osteoclastogenesis. To this aim, we explored the
effect of BO on CHIT1 and YKL40 expression in monocytes
after 21 days from the beginning of OC differentiation. We found
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FIGURE 2 | In OCs treated with BO the chitinases protein expression was significantly decrease for the two isoforms of CHIT1 (39 kDa lysosomal and
50 kDa secretory), for the two component of YKL40 (50 kDa cytoplasmatic and secretory) and for the two component of MMP9 (92 kDa
cytoplasmatic and secretory) when BO was added to culture. All results are compared to OCs without BO. Values are shown as means  SD of three
independent experiments. The figure shows representative data from one of three replicate experiments **P<0.001, ***P<0.0001.
that BO led to a down-regulation of both the mRNA in a dose-
dependent manner (p<0.001 and p<0.0001 respectively at 2.5
and 5 nM of BO for CHIT1; p<0.0001 at 5 nM for YKL40;
Figures 1C,D), suggesting that BO inhibits osteoclastogenesis
through, at least in part, downregulation of chitinases expression.
BO Affects Both Cytoplasmic and Secretory
Component of CHIT1 and YKL40 Protein
Since it has been reported that MMP9 expression is closely
associated with CHIT1 and YKL40 production (Malaguarnera
et al., 2009; Di Rosa et al., 2014), we next investigated what
component (cytoplasmic and secretory) was affected by BO
treatment after 21 days from the beginning of OC differentiation.
We found that BO was able to induce a significant decrease
of both the components of CHIT1, YKL40, and MMP9 in a
dose-dependent manner, with the exception of the cytoplasmic
component of YKL40 at a dose of 2.5 nM (Figure 2).
BO Modulates CHIT1 Activity During OCs
Differentiation
Afterward, we evaluated whether the secreted CHIT1 was
enzymatically active in OCs after 3, 5, 7, 15, and 21 days from
the beginning of differentiation and BO exposure. We found that
2.5 nM BO significantly decreased CHIT1 activity of 34  8 and
29 8%at 15 and 21days (p<0.01;Figure 3). Five nMBOwas able
to decrease the protein activity during all differentiation process
(70  5, 62  1, 65  4, and 68  4% respectively at 5, 7, 15, and
21 days; p<0.001).
Subcellular Distribution of CHIT1 and YKL40 in
OCs After Exposure to BO
Our data suggest that BO inhibits osteoclastogenesis through, at
least in part, downregulation of YKL40 and CHIT1 expression
and activity. We further looked at the subcellular distribution
of CHIT1 and YKL40 by immunofluorescence in OCs after
FIGURE 3 | CHIT1 enzyme activity was measured in cell-free
supernatants. Culture supernatants were analyzed, enzyme activity
calculated and expressed as nanomoles per liter per hour. Data are expressed
as mean  SD of at least three independent experiments. *P<0.01,
**P<0.001 compared to the respective time in OCs without BO.
21 days from the beginning of differentiation to examine if
their localization could undergo a change after BO exposure.
Because the maximum modulation of chitinases was observed
with 5 nM BO, we chose this dose as a point of reference for
the assay. Immunofluorescence analysis showed the characteristic
morphology of OCs that are multinucleated large size-cells (about
200 mm; Figure 4D). CHIT1 and YKL40 distribution were purely
cytoplasmic (Figures 4H and 5L). Treatment with BO led to a
reduction of cells size and nuclei numbers (Figures 4A and 5E).
No nuclear localizationwas detected for CHIT1 after BO exposure
(Figure 4). On the contrary, BO treatment was able to induce
nuclear translocation of YKL40 (Figures 5D,H). Remarkably,
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FIGURE 4 | CHIT1 was detected with Alexa Fluor 594-conjugated Affini Pure Goat-anti-Rabbit IgG (Red). Most of the cells in immunostaining for CHIT1
show a characteristic distribution pattern, the signal being localized only in the cytoplasm. The Blue represents DAPI nuclear counterstain. It is important to note the
many nuclei present per cell. Scale bars equal 20 mm. (A,E) Double staining of CHIT1 in red and nuclei in blue. (B,F) CHIT1 staining in red alone. (C,G) nuclear
staining with DAPI alone. (D,H) Z-stack confocal images, double staining of CHIT1 in red and nuclei in blue.
the protein localized into the nucleus after BO exposure also in
mononuclear cells (Figure 5D). Thus, these data indicated that BO
was also able to affect YKL40 car localization.
BO Modulates CHIT1 and YKL40 Expression and
Activity in MM Cell Lines
Since recent observations suggest that malignant plasma cells
take part in bone destruction (Silvestris et al., 2009), we next
analyzed CHIT1 activity in MM cell lines (U266, SKM-M1, and
MM1). High activity levels were found with a mean value of
466  111.29, 216  19.07, and 98  41.44 respectively for
U266, SKM-M1, and MM1 (Figure 6A). Since U266 showed the
highest CHIT1 activity levels, we analyzed CHIT1 and YKL40
mRNA expression in MM cell lines using U266 as control. Also
chitinases expression resulted higher in U266 than SKM-M1 and
MM1cells (Figure 6B); therefore, we choseU266 as cellularmodel
to evaluate effect of BO on CHIT1 and YKL40 expression in
MM cells. We found that BO was able to down-regulate CHIT1
and YKL40 mRNA expression in a dose-dependent manner
(p<0.0001; Figure 6C), suggesting that BOmay impair PC ability
to participate in bone resorption.
Next, we evaluated the capacity of bone matrix digestion by
U266 and the involvement of CHIT1 and YKL40 in the digestive
process. The cells were plated onto dentin disks (DDs) and divided
into different groups: U266 alone (control); cells transfected with
scrambled random siRNA (SS; negative control); cells transfected
with CHIT1 or YKL40 siRNAs andU266 co-transfected with both
siRNAs. Digestive activity was observed both in DDs with U266
alone and in the negative control group (Figure 6D). Treatment
with CHIT1 and YKL40 siRNAs alone or in combination, resulted
in a significant reduction of about 21.98  5.2 and 25.08  3% in
the digestion activity compared to the negative control (p<0.003).
Interestingly, inhibition of both CHIT1 and YKL40 led to a
decrease of 82.85 7% in the digestion activity of about compared
to negative control (p<0.0001). Taken together these data strongly
suggest that PC act as functional OCs through expression and
activity of chitinases.
Discussion
It has been known thatOCs and their activators are very important
for myeloma cell growth and survival (Hongming and Jian, 2009).
Terpos et al. (2006) reported that BO treatment significantly
reduced serum DKK-1, sRANKL as well as bone resorption
markers including TRAP-5b and CTX, promoting normalization
of bone remodeling in MM patients.
Recent studies have shown that BO treatment determines
a reduction of osteoclastogenesis and bone digestion in MM
patients (vonMetzler et al., 2007; Hongming and Jian, 2009). This
inhibitory effect is likely linked to the ability of the drug to block
the proteasome activity and activateNF-kBpathways (Qiang et al.,
2012). We here demonstrated, for the first time, that BO inhibits
osteoclastogenesis also through downregulation of CHIT1 and
YKL40 in a dose-dependent manner, leading to reduction of bone
resorption. In fact, chitinases not only are crucial during the
osteoclastogenesis process, but are also directly involved in the
digestive process (Di Rosa et al., 2014).
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FIGURE 5 | YKL40 was detected with Alexa Fluor 594-conjugated Affini Pure Goat-anti-Rabbit IgG (Red). Most of the cells in immunostaining for YKL40
show a characteristic distribution pattern, the signal being localized in the cytoplasm and in the nucleo in cell treated with BO. The Blue represents DAPI nuclear
counterstain. It is important to note the many nuclei present per cell. Scale bars equal 10 mm. (A,E,I) Double staining of YKL40 in red and nuclei in blue. (B,F,J)
CHIT1 staining in red alone. (C,G,K) nuclear staining with DAPI alone. (D,H,L) Z-stack confocal images, Double staining of YKL40 in red and nuclei in blue.
First, we confirmed that BO exposure during OC
differentiation led to the inhibition of OCmarkers expression and
reduced the bone digestion ability of OCs in a dose-dependent
manner. We further showed that drug treatment down-regulated
expression of CHIT1 and YKL40 in a dose-dependent manner.
In particular, BO affected both the component (cytoplasmic
and secretory) of CHIT1, YKL40 and MMP9, whose expression
is closely associated with chitinases production. Also CHIT1
activity was affected by BO during OCs differentiation. This
reduction is closely related with down-regulation of mRNA and
secretory/lysosome CHIT1 protein levels.
Treatment with BO during OC differentiation modulated also
the expression of YKL40. This chitinase does not have the catalytic
site but it is able to bind chitin through its chitin binding domain
(CBM). It has been demonstrated that the expression of YKL40 is
linked to the NF-kB pathways (Recklies et al., 2005; Bhat et al.,
2008; Tang et al., 2013) and this could explain the observed
reduction of YKL40 in OCs treated with BO. Many reports have
shown that high levels of plasma YKL40 are associated with
increased bone lesions in patients with MM (Mylin et al., 2006,
2008, 2009), but its role is not yet understood. Recently, our group
has demonstrated that silencing YKL40 with siRNA in human
mature OCs results in decreased levels of the matrix degrading
collagenase MMP9 as well as decreased bone resorptive activity
in vitro, suggesting a key role for YKL40 in OC function (Di
Rosa et al., 2014). In accordance with our findings, Mylin et al.
(2015) demonstrated that serum YKL-40 is a new independent
prognostic marker for skeletal complications in MM patients.
We also observed and reported for the first time that YKL40 is
able to translocate into the nucleus in OCs exposed to BO during
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FIGURE 6 | The MM cells line (U266, SKM-M1, and MM1) express different levels of CHIT1 activity (A) and chitinase mRNA expression CHIT1 and
YKL40 (B). The treatment of U266 with BO (2.5 and 5 nM) for 24 h reduce the mRNA expression of CHIT1 and YKL40 (C). Determination of resorption pits on dentin
disk showed a significant reduction in the cells treated with CHIT1 siRNA, YKL40 siRNA and in the co-silencing with CHIT1 and YKL40 siRNA (DS) compared to the
negative control (SS) (D). Results are expressed as the number of resorption pits. Data are expressed as mean  SD of at least three independent
experiments.*P<0.01, **P<0.001, ***P<0.0001.
differentiation. We can hypothesize that a structural change of
the cytoskeleton induced by BO leads YKL40 to bind F-actin
(Poglazov and Livanova, 1986).
Silvestris et al. (2009) has recently discussed the role of
malignant PCs in bone disease of MM patients, demonstrating
that PCs produced pits on experimental osteologic substrates in
vitro without defining the molecular events. In this work we
chose to investigate if CHIT1 and YKL40 are involved in their
capacity of bone resorption. Since from a preliminary analysis,
U266 expressed higher CHIT1 activity and showed higher levels
of CHIT1 and YKL40 mRNA than SKM-M1 and MM1 MM cell
lines, we chose U266 cells as MM model. By silencing CHIT1
and YKL40 alone with siRNA, we found a reduction of the U266
digestion activity; we also observed an additional effect using
the two siRNA in combination. Interestingly, exposure of U266
to BO was able to decrease CHIT1 and YKL40 expression. All
these data suggest that BO treatment in MM patients results in
an improvement of bone remodeling through the stimulation
of bone formation and the suppression of bone resorption not
only by OCs but potentially also by PCs; all these BO effects
contribute to the antimyeloma efficacy of this drug (Pennisi et al.,
2009).
In conclusion, these findings strongly support an evolving
concept regarding the role of CHIT1 and YKL40 in MM
disease. This is the first study reporting not only that CHIT1
may emerge as an useful serum marker with YKL40 for
osteolysis, but also that it is functionally and directly involved
in MM osteolytic lesion. Therefore, MM patients with elevated
serum levels of CHIT1 and YKL40 may have an increased
osteolytic activity and a faster progression of bone disease.
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BO treatment inhibits osteoclastogenesis by reducing CHIT1 and
YKL40 expression. Additional studies to disclose the molecular
mechanisms regulating the expression of these chitinases in MM
patients and their mechanism of action in the bone degenerative
disease would be very important to develop novel strategies of
treatment for the management of degenerative skeletal diseases.
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